Shah, Urvi A. http://orcid.org/0000-0001-8419-1091
Parikh, Richa http://orcid.org/0000-0002-5270-104X
Castro, Francesca http://orcid.org/0000-0003-2023-5483
Bellone, Matteo http://orcid.org/0000-0002-2586-2569
Lesokhin, Alexander M.
Article History
Received: 31 December 2022
Revised: 23 February 2023
Accepted: 9 March 2023
First Online: 30 March 2023
Competing interests
: UAS reports grants from NIH/NCI Cancer Center Support Grant P30CA008748, MSK Paul Calabresi Career Development Award for Clinical Oncology K12CA184746, Paula and Rodger Riney Foundation, Allen Foundation Inc, Parker Institute for Cancer Immunotherapy at MSK, HealthTree Foundation, and International Myeloma Society as well as non-financial support from American Society of Hematology Clinical Research Training Institute, TREC Training Workshop R25CA203650 (PI: Melinda Irwin). UAS also reports research funding support from Celgene/BMS, Janssen, Plantable, Sabinsa pharmaceuticals, VeggieDoctor and M and M labs to the institution, non-financial research support; personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH LifeSciences, Intellisphere, Phillips Gilmore Oncology Communications, and RedMedEd outside the submitted work. MB has received honoraria from Bristol Meyers Squibb; Co-owner of the patent # EP18209623.0 - Strategies to improve colonization and expression of Prevotella melaninogenica in the gut of patients affected by IL-17-mediated diseases. AML reports grants from Bristol Myers Squibb and Genentech; grants, personal fees, and non-financial support from Pfizer; and grants and personal fees from Janssen outside the submitted work. AML has a patent for US20150037346A1 licensed and with royalties paid from Serametrix, Inc. No disclosures were reported by the other authors.